---
title: "Scientific Exchange vs Promotion: 6 Clear Lines to Hold"
description: "Scientific exchange or promotion? Six lines that keep a regen product company's science talks apart from sales decks, rep pitches, and promotional claims."
url: "https://regenportal.com/scientific-exchange-vs-promotion/"
---

# Scientific Exchange vs Promotion: 6 Clear Lines to Hold

- [Oscar Tellez](https://regenportal.com/oscar-tellez/)
- Published October 28, 2026

![Two dark shelving runs divided by a glass wall with a green base light](https://regenportal.com/wp-content/uploads/2026/09/scientific-exchange-vs-promotion.png)

Scientific exchange is how a product company discusses the science with physicians without making a sales claim. Promotion is how it sells. Most regen product companies mix the two in one deck, one rep, and one shared folder. This post gives the owner or medical affairs lead six lines that keep the two apart, and shows what happens when a poster slide lands in a sales deck.

**TLDR:** Scientific exchange and promotion are separate jobs with separate people, triggers, materials, and records. FDA’s final guidance on sharing science about unapproved uses is its current word for drugs, devices, and biologics. Whether it reaches HCT/Ps is a counsel question. HCT/P companies should hold the same six lines, because their claim rules are stricter, not looser. One borrowed slide can turn a science conversation into a promotional claim. Read on for the six lines, the mistakes we flag most, and a scenario built around one poster.

**Important Note**

This article is for educational purposes only and does not constitute legal, medical, or regulatory advice. Marketing strategies discussed should be reviewed by qualified legal counsel before implementation, particularly regarding FDA, FTC, and state-specific advertising regulations. Regen Portal is a marketing and consulting company, not a law firm. Nothing here implies FDA approval of any product or any use. Most cell, tissue and exosome products marketed to patients are not FDA approved, and the few cell-based products the FDA has approved are approved only for specific labeled indications. Nothing here promises a marketing or business outcome. Regulations change and enforcement varies by state. Confirm current requirements with qualified legal and compliance counsel before you act on anything you read here.

Physicians buy on evidence. Training, use cases, peer discussion, and studies comparing one method with another move them far more than any pitch. For a product company with real science, that is an advantage. It is also exactly where the legal trouble starts.

Physicians want the research talk, so sales wants to have it. The moment a rep opens a study to close a deal, the study becomes a sales claim. That claim has to meet every ad rule. The six lines below keep both talks clean.

## Why Scientific Exchange and Promotion Cannot Share a Folder

Scientific exchange is the open talk about data, even data that does not help you. Promotion is anything meant to move a product. The law treats them differently because of intent. A study shared to sell reads as a claim. The same study, sent by science staff to answer a doctor’s question, with its limits, reads as science.

Here is what we see when we ask a vendor for the proof behind a sentence. What comes back is usually vendor materials, sometimes a certificate of analysis or a public clinical trial, and often not much at all. That thin file then backs the pitch and is also handed over as “the science.” Neither use holds up. Split the two, and the doctor still gets the full paper while the rep gets a clean deck.

The next section covers FDA’s guidance.

## What FDA’s Guidance Says About Sharing Science

FDA’s current word is its [January 2025 final guidance](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/communications-firms-health-care-providers-regarding-scientific-information-unapproved-uses) on sharing science about unapproved uses with providers. It covers drugs, devices, and biologics, and it replaced older drafts on sharing papers. FDA’s page still says it is not for current implementation, so counsel confirms whether to rely on it. It deals with approved or cleared products, so whether it reaches a 361 HCT/P is a question for counsel.

An older [draft guidance on unsolicited requests](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/responding-unsolicited-requests-label-information-about-prescription-drugs-and-medical-devices) from December 2011 covers prescription drugs and medical devices. It is still a draft, not binding, and it does not cover 361 HCT/Ps directly.

The 2011 draft draws a line between requests the firm prompted and requests it did not. An unsolicited request comes from a person fully independent of the firm. If the firm or its reps prompted it in any way, it is solicited. A rep who hints at an unapproved use and invites questions has solicited the request. The reply then counts as promotion.

For a true unsolicited request, the draft says medical or science staff should write the reply. Sales and marketing give no input. The reply should be truthful, accurate, balanced, and scientific in tone. It should include data that cut against the product.

The reply should also come with the approved labeling, a statement that FDA has not approved the use, and a full list of references. Public requests on social media get only the firm’s contact details. The science is then shared one to one, in private.

FDA’s [social media page for industry](https://www.fda.gov/about-fda/center-drug-evaluation-and-research-cder/industry-using-social-media) lists this draft alongside three others on internet and social media promotion. The six lines below turn that thinking into a working policy.

## Lines 1 to 3: Who Speaks, What Triggers It, and What Is Shared

Line 1 is who speaks. Scientific exchange comes from medical affairs or a scientific lead. Promotion comes from sales and marketing. A person wears one hat per conversation. If one person holds both roles, they need two written scripts.

Line 2 is what triggers it. Scientific exchange starts with a question the physician asked on their own. Promotion starts with a pitch. If the rep raised the topic, it is a pitch, even if the doctor asked a follow-up. Define “unsolicited” in plain words and train every rep on it.

Line 3 is what is shared. Scientific exchange shares the full paper, with its limits, sample size, comparison arm, and funding. Promotion shares a slide. A poster chart on a slide, with the caveats cut, is not science. It is a claim, and it needs evidence that fits the product and the use. The [FTC’s health products guidance](https://www.ftc.gov/business-guidance/resources/health-products-compliance-guidance) says a firm must have competent and reliable scientific evidence before a health claim goes out.

Sales and science each get their own materials. This table makes the split plain.

Element Scientific Exchange Promotion

Who speaks Medical or scientific staff Sales and marketing

Trigger A question the physician raised The company’s own outreach

Material The full publication and its limits A reviewed claim sheet

Lines 4 to 6 cover what is said, where it lives, and how it is recorded.

## Lines 4 to 6: Unapproved Uses, Where It Lives, and How It Is Recorded

Line 4 is what is said about unapproved uses. In scientific exchange, an unapproved use can be discussed when a physician asks. The reply says plainly that the use is not approved or cleared, and it shows the data on both sides. In promotion, an unapproved use is never raised, not on a slide, at a booth, or in a text. If it is not on the claim sheet, the rep says, “I will have medical affairs reach out.”

Line 5 is where it lives. Science materials live in a separate library that medical affairs owns, with a log of who got what. Sales materials live in the sales folder, and each one has passed a claims review. The two never share a file. If a rep can drag a poster into a deck, the wall does not exist.

Line 6 is how it is documented. Every science reply gets a record: who asked, what was sent, and when. Every sales item gets one too: who reviewed it and against which claim sheet. On client content, we run two review passes. Our review team checks claim language, disclosures, accuracy, and structure, and the client’s own clinician signs off on anything clinical. A science library needs the same two signatures.

With all six lines written down, the question becomes whether they apply to HCT/P companies at all.

## Why HCT/P Companies Need the Same Scientific Exchange Discipline

Yes, and more so. FDA’s guidance was written for approved or cleared products, and counsel decides whether any of it reaches a 361 HCT/P. But a 361 product has less room for claims than an approved drug, not more. An approved drug has a label full of uses a rep may discuss. A 361 product has a homologous use description and no approved indications at all.

So every clinical claim for a 361 product is a claim FDA has not reviewed. The [361 product marketing rules](https://regenportal.com/361-product-marketing-hctp-companies/) cover the four criteria. They also show why a treatment word on a slide puts the product’s status at risk. A rep who shares a study and says the product treats a condition has made a claim with no label behind it.

So the HCT/P company should hold the six lines harder, not softer. Medical affairs answers science questions. Sales works from a claim sheet that describes the product as the listing describes it. The [claims substantiation steps](https://regenportal.com/claims-substantiation-ftc-regen-marketing/) the FTC expects apply to every sentence in that sheet. To show physicians your research, learn how to [build authority with content](https://regenportal.com/stem-cell-content-marketing-how-to-build-authority/) without claims the product cannot carry.

The lines are clear on paper. The mistakes below are how they get crossed in practice.

## Common Mistakes That Turn Scientific Exchange Into a Sales Claim

The first mistake is the borrowed slide. Sales likes a chart from a poster, and it lands on slide 7 with the caption trimmed. When a product company hands us a deck, one-pager, or website to review, we flag three things first. They are non-compliant claims, wording too complex for the buyer, and weak graphics. The borrowed slide is usually the source of the first one.

The second mistake is the rep who plays scientist. A rep hears a question about an unapproved use and answers from memory. That answer is promotion. Train reps to hand it to medical affairs.

The third mistake is the science library with no gate. Reprints sit in a shared drive next to the sales deck. A reprint mailed by sales, with a highlighted paragraph, is a sales claim with a citation.

The fourth mistake is the KOL who is really a spokesperson. A paid speaker who presents the company’s slides is doing promotion, not scientific exchange. A [KOL program that stays compliant](https://regenportal.com/kol-program-regen-product-companies/) keeps speaker content separate from the sales deck and discloses the relationship.

The fifth mistake is the product page that quotes the science. Product pages are promotion. If a page needs a study to make its point, the point is likely a claim. In September 2026, an FDA warning letter quoted a supplier’s white paper, hedges and all, as proof of intended use. For a cell product, no white paper, viability study or cell count belongs on a public page or in a deck. The rules for [writing exosome pages safely](https://regenportal.com/write-exosome-service-pages-that-dont-trigger-fda/) show how the same problem looks on the clinic side.

A scenario shows how this can start with one slide.

## Picture a Product Company With One Borrowed Poster Slide

Picture a birth tissue product company in a mid-sized market. Its medical director presented a poster from a small case series. The poster lists a sample size, a follow-up window, and a limits section that says the series had no control group.

A rep asks for a stronger deck. Marketing pulls the chart and drops the limits. The new caption says the product “supports” a condition the listing never names. The deck goes out to clinics, and some copy the caption onto their websites. Now a treatment-adjacent claim about a 361 product sits on the deck and on clinic pages.

Here is the same company with the six lines in place. The poster lives in the medical affairs library. When a physician asks about that condition, medical affairs sends the full poster and its limits. It adds a plain note that the use is not approved, and it logs the request. The sales deck describes the product as the listing describes it. Clinics that copy from the deck copy compliant language.

The research talk still happens, with the right people and the whole paper on the table. The FAQ below covers the questions we get most.

## Frequently Asked Questions

### Is Scientific Exchange Legal for a 361 HCT/P Company?

Counsel decides for your product. FDA’s guidance on sharing science was written for approved or cleared drugs, devices, and biologics. A 361 product has no approved indications, so any clinical claim is about an unapproved use. Sharing research to answer a physician’s own question, with limits and no claim, is not the same act as pitching it. Structure it that way, document it, and have counsel review the policy.

### Can a Sales Rep Ever Hand a Physician a Study?

The safer answer is no, and the reason is intent. When sales hands over a study, the study becomes part of the pitch. FDA’s draft guidance says replies to unsolicited requests should come from medical or scientific staff with no input from sales or marketing. Route the request to medical affairs. The physician gets the paper either way, and the company gets a record instead of a risk.

### What Counts as an Unsolicited Request?

A request the physician raised on their own, with no prompt from your company or your reps. If a rep hinted at a use or asked a leading question, the request was solicited. The answer is then promotion. Write a plain definition, give examples, and make sure every rep can say it out loud.

### What Should a Scientific Exchange Record Contain?

Who asked, what they asked, what was sent, who sent it, and the date. Add a copy of the exact materials and the approval-status statement that went with them. FDA’s draft guidance lists the requestor’s name, address, and affiliation and the information provided. A record like that shows the exchange was a reply to a request, not a campaign.

### How Does the FTC Fit Into Scientific Exchange?

The FTC governs the promotion side. Its health products guidance says a firm needs competent and reliable scientific evidence before a health claim goes out. The evidence has to match the product and the use. A study that becomes a sales slide has to pass that test. Keep science and sales apart and the FTC question gets simpler.

## Key Takeaways

- Scientific exchange is the open discussion of data with its limits, and promotion is any communication meant to move product.
- FDA’s final guidance on sharing science is its current word, the unsolicited requests guidance is still a draft, and counsel decides how either applies to an HCT/P.
- Medical or scientific staff answer science questions, and sales works only from a reviewed claim sheet.
- A request counts as unsolicited only when the physician raised it without any prompt from the company.
- The full publication with its limits belongs to scientific exchange, and a trimmed chart on a sales slide is a claim.
- Unapproved uses are discussed only in reply to a request, with a plain statement that the use is not approved.
- Separate libraries and a log of every response are what turn a policy into a defense.

## Your Next Step

Physicians are moved by research and discussion. Scientific exchange done right gives them that, and gives sales a clean deck. The six lines do not limit the science you share. They let you share it.

If you want a second set of eyes on the sales deck, the science library, or the policy between them, that is where we start. Our [compliance review for product companies](https://regenportal.com/marketing-compliance/) begins with a full inventory of what is live, each flagged phrase with its reason, and a lower-risk rewrite.

PS: Send us your current sales deck and we will review it against these six lines at no cost.

Email: [hello@regenportal.com](mailto:hello@regenportal.com)

YouTube: [Subscribe to the channel](https://www.youtube.com/@oatellez)

## About Regen Portal

Regen Portal is a marketing and consulting company built for the regenerative medicine industry. We handle practice consulting, marketing compliance, search engine optimization, content creation, social media management, paid advertising, website development, branding, and AI and ops consulting for clinics, manufacturers, distributors, and independent providers. For more on me and how we work, visit Regen Portal and [contact us](https://regenportal.com/contact-us/).

## About the Author

[Oscar Tellez](https://regenportal.com/oscar-tellez/) is the founder of Regen Portal, a marketing and consulting company built for the regenerative medicine industry. He has been in this industry since 2015. He started in medical sales and has worked with PRP since 2016. He has reached hundreds of practices and over 200 doctors through sales, teaching and marketing. He holds a B.S. in Exercise Science and Health Promotion from Florida Atlantic University.

[Add Regen Portal as a Preferred Source on Google](https://www.google.com/preferences/source?q=regenportal.com)

[PrevPreviousPractice Valuation for Regen Clinics: 8 Practical Value Drivers](https://regenportal.com/practice-valuation-regen-clinics/)

[NextProduct Recall Communication: A Practical 5-Step Clinic PlanNext](https://regenportal.com/product-recall-communication-clinics/)

## Table of Contents

### [What Should I Charge for PRP Injections?](https://regenportal.com/what-to-charge-for-prp-injections/)

November 3, 2026

### [Are Exosomes Legal? What a Clinic Owner Needs to Know](https://regenportal.com/are-exosomes-legal/)

November 2, 2026

### [Biologics Product Pages: 7 Smart Rules for Manufacturers](https://regenportal.com/biologics-product-pages-compliant/)

October 30, 2026

```json
{"@context":"https:\/\/schema.org","@graph":[{"@type":"BlogPosting","@id":"https:\/\/regenportal.com\/scientific-exchange-vs-promotion\/#article","mainEntityOfPage":"https:\/\/regenportal.com\/scientific-exchange-vs-promotion\/","headline":"Scientific Exchange vs Promotion: 6 Clear Lines to Hold","description":"Scientific exchange or promotion? Six lines that keep a regen product company's science talks apart from sales decks, rep pitches, and promotional claims.","image":["https:\/\/regenportal.com\/wp-content\/uploads\/2026\/09\/scientific-exchange-vs-promotion.png"],"url":"https:\/\/regenportal.com\/scientific-exchange-vs-promotion\/","datePublished":"2026-10-28","dateModified":"2026-10-28","inLanguage":"en-US","articleSection":"Regulatory","author":{"@type":"Person","@id":"https:\/\/regenportal.com\/oscar-tellez\/#person","name":"Oscar Tellez","url":"https:\/\/regenportal.com\/oscar-tellez\/","image":{"@type":"ImageObject","url":"https:\/\/regenportal.com\/wp-content\/uploads\/2026\/05\/Oscar-Tellez-e1778268697402.png"},"jobTitle":"Founder","description":"I've been inside this industry since 2015. I help clinics, manufacturers, distributors and every other kind of business in this field grow, with consulting first and then marketing that follows the rules.","worksFor":{"@type":"MarketingAgency","@id":"https:\/\/regenportal.com\/#organization","name":"Regen Portal","url":"https:\/\/regenportal.com\/"},"knowsAbout":["Regenerative Medicine Marketing","Medical SEO","Cash-Based Practice Growth","Stem Cell Therapy Marketing","FDA\/FTC Healthcare Advertising Compliance","Brand Strategy for Medical Practices","Paid Advertising for Medical Practices"],"sameAs":["https:\/\/www.linkedin.com\/in\/o-tellez\/","https:\/\/www.instagram.com\/realoscartellez\/","https:\/\/www.youtube.com\/@oatellez"],"alumniOf":{"@type":"CollegeOrUniversity","name":"Florida Atlantic University"}},"publisher":{"@type":"MarketingAgency","@id":"https:\/\/regenportal.com\/#organization","name":"Regen Portal","url":"https:\/\/regenportal.com\/","logo":{"@type":"ImageObject","url":"https:\/\/regenportal.com\/wp-content\/uploads\/2025\/12\/Regen-Portal-Footer-Logo.png"}},"name":"Scientific Exchange vs Promotion: 6 Clear Lines to Hold"},{"@type":"Place","@id":"https:\/\/regenportal.com\/#place","geo":{"@type":"GeoCoordinates","latitude":"25.7469247","longitude":"-80.2593893"},"hasMap":"https:\/\/www.google.com\/maps\/search\/?api=1&query=25.7469247,-80.2593893","address":{"@type":"PostalAddress","addressLocality":"Miami","addressRegion":"Florida","addressCountry":"US","streetAddress":"226 ALMERIA AVE #1043","postalCode":"33134"}},{"@type":["Organization"],"@id":"https:\/\/regenportal.com\/#organization","name":"Regen Portal","url":"https:\/\/regenportal.com","sameAs":["https:\/\/www.facebook.com\/regenportal","https:\/\/linkedin.com\/company\/regen-portal\/","https:\/\/www.instagram.com\/regenportal\/","https:\/\/search.sunbiz.org\/Inquiry\/corporationsearch\/SearchResultDetail?inquirytype=EntityName&directionType=Initial&searchNameOrder=REGENPORTAL%20L250005352700&aggregateId=flal-l25000535270-3e485d68-27cf-42d4-aa19-e30d3a213661&searchTerm=REGENORTHORX%2C%20LLC&listNameOrder=REGENORTHORX%20L160000490770"],"email":"hello@regenportal.com","address":{"@type":"PostalAddress","addressLocality":"Miami","addressRegion":"Florida","addressCountry":"US","streetAddress":"226 ALMERIA AVE #1043","postalCode":"33134"},"logo":{"@type":"ImageObject","@id":"https:\/\/regenportal.com\/#logo","url":"https:\/\/regenportal.com\/wp-content\/uploads\/2025\/12\/foter-logo.png","contentUrl":"https:\/\/regenportal.com\/wp-content\/uploads\/2025\/12\/foter-logo.png","caption":"Regen Portal","inLanguage":"en-US","width":"464","height":"185"},"priceRange":"$$$","contactPoint":[{"@type":"ContactPoint","telephone":"+1 786-434-9553","contactType":"customer support"}],"openingHours":["Mo,Tu,We,Th,Fr 09:00-17:00"],"description":"Regen Portal is a consulting and marketing firm for the regenerative medicine industry, from clinics to manufacturers and distributors. We have been in this industry since 2015, and we take on about five clients a year.","legalName":"Regen Portal LLC","foundingDate":"2022","numberOfEmployees":{"@type":"QuantitativeValue","value":"10"},"location":{"@id":"https:\/\/regenportal.com\/#place"}},{"@type":"WebSite","@id":"https:\/\/regenportal.com\/#website","url":"https:\/\/regenportal.com","name":"Regen Portal","alternateName":"regenportal.com","publisher":{"@id":"https:\/\/regenportal.com\/#organization"},"inLanguage":"en-US"},{"@type":"ImageObject","@id":"https:\/\/regenportal.com\/wp-content\/uploads\/2026\/09\/scientific-exchange-vs-promotion.png","url":"https:\/\/regenportal.com\/wp-content\/uploads\/2026\/09\/scientific-exchange-vs-promotion.png","width":"1250","height":"1250","caption":"Scientific exchange vs promotion as two dark shelving runs divided by a glass wall with a green base light","inLanguage":"en-US"},{"@type":"BreadcrumbList","@id":"https:\/\/regenportal.com\/scientific-exchange-vs-promotion\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":"1","item":{"@id":"https:\/\/regenportal.com","name":"Home"}},{"@type":"ListItem","position":"2","item":{"@id":"https:\/\/regenportal.com\/blog\/","name":"Blog"}},{"@type":"ListItem","position":"3","item":{"@id":"https:\/\/regenportal.com\/category\/regulatory\/","name":"Regulatory"}},{"@type":"ListItem","position":"4","item":{"@id":"https:\/\/regenportal.com\/scientific-exchange-vs-promotion\/","name":"Scientific Exchange vs Promotion: 6 Clear Lines to Hold"}}]},{"@type":["WebPage","FAQPage"],"@id":"https:\/\/regenportal.com\/scientific-exchange-vs-promotion\/#webpage","url":"https:\/\/regenportal.com\/scientific-exchange-vs-promotion\/","name":"Scientific Exchange vs Promotion: 6 Clear Lines to Hold","datePublished":"2026-10-28T10:00:00-04:00","dateModified":"2026-10-28T10:00:00-04:00","isPartOf":{"@id":"https:\/\/regenportal.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/regenportal.com\/wp-content\/uploads\/2026\/09\/scientific-exchange-vs-promotion.png"},"inLanguage":"en-US","breadcrumb":{"@id":"https:\/\/regenportal.com\/scientific-exchange-vs-promotion\/#breadcrumb"},"mainEntity":[{"@type":"Question","name":"Is Scientific Exchange Legal for a 361 HCT\/P Company?","acceptedAnswer":{"@type":"Answer","text":"Counsel decides for your product. FDA's guidance on sharing science was written for approved or cleared drugs, devices, and biologics. A 361 product has no approved indications, so any clinical claim is about an unapproved use. Sharing research to answer a physician's own question, with limits and no claim, is not the same act as pitching it. Structure it that way, document it, and have counsel review the policy."}},{"@type":"Question","name":"Can a Sales Rep Ever Hand a Physician a Study?","acceptedAnswer":{"@type":"Answer","text":"The safer answer is no, and the reason is intent. When sales hands over a study, the study becomes part of the pitch. FDA's draft guidance says replies to unsolicited requests should come from medical or scientific staff with no input from sales or marketing. Route the request to medical affairs. The physician gets the paper either way, and the company gets a record instead of a risk."}},{"@type":"Question","name":"What Counts as an Unsolicited Request?","acceptedAnswer":{"@type":"Answer","text":"A request the physician raised on their own, with no prompt from your company or your reps. If a rep hinted at a use or asked a leading question, the request was solicited. The answer is then promotion. Write a plain definition, give examples, and make sure every rep can say it out loud."}},{"@type":"Question","name":"What Should a Scientific Exchange Record Contain?","acceptedAnswer":{"@type":"Answer","text":"Who asked, what they asked, what was sent, who sent it, and the date. Add a copy of the exact materials and the approval-status statement that went with them. FDA's draft guidance lists the requestor's name, address, and affiliation and the information provided. A record like that shows the exchange was a reply to a request, not a campaign."}},{"@type":"Question","name":"How Does the FTC Fit Into Scientific Exchange?","acceptedAnswer":{"@type":"Answer","text":"The FTC governs the promotion side. Its health products guidance says a firm needs competent and reliable scientific evidence before a health claim goes out. The evidence has to match the product and the use. A study that becomes a sales slide has to pass that test. Keep science and sales apart and the FTC question gets simpler."}}]}]}
```